Therefore, a treatment with anti-PD-1 blocking antibodies to increase the number of CD8 + memory T cells in the tumour microenvironment may be useful as an immune prevention approach to antagonize the immune evasion of tumour cells [97–99]. This evidence concerns the gene CD8A and neoplasm.